Merck stops development of combination diabetes drug

11/19/2012 | Reuters

Merck & Co. cited business reasons in its decision to stop development of a diabetes pill that would have combined its Januvia and a generic version of Lipitor, Pfizer's cholesterol drug. Drugmakers see combination drugs as a way to reduce the number of medications patients take. Merck already markets Juvisync, which is Januvia plus the cholesterol drug simvastatin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC